FDA Authorizes Additional Batch of the J&J COVID-19 Vaccine

Article

An additional batch of the Janssen COVID-19 vaccine has been authorized by FDA under the Emergency Use Authorization.

FDA authorized an additional batch of Janssen’s COVID-19 vaccine manufactured at Emergent BioSolutions’ facility in Baltimore under Emergency Use Authorization (EUA), the agency announced on July 2, 2021.

Thus far, four batches have been authorized to be manufactured at the Emergent BioSolutions plant in the Janssen EUA, though the facility isn’t officially an authorized manufacturing facility. FDA reviewed facility records, including quality testing, and concluded the batches were suitable for use.

FDA said it will continue to work through issues that arise at the Emergent facility with Janssen and Emergent BioSolutions management.

Previously, FDA authorized the use of two batches of Janssen’s vaccine under EUA on June 11, 2021.

Source: FDA

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Leroy Hood, MD, PhD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Related Content